Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
ALT Analyst Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ALT Stock 12 Month Forecast
Average Price Target
$21.86
▲(288.97%Upside)
| Highest Price Target$28.00 | Average Price Target$21.86 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$5.5
Hold
-2.14%
Downside
Reiterated
05/29/25
Citizens JMP
$25
Buy
344.84%
Upside
Reiterated
06/05/25
Stifel Nicolaus
$18
Buy
220.28%
Upside
Initiated
06/01/25
H.C. Wainwright
$12
Buy
113.52%
Upside
Reiterated
05/22/25
Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT) and Alpha Tau Medical Ltd (NASDAQ: DRTS)We assess Altimmune using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)-based methodology. We assign probabilities of success for pemvidutide (ALT-801) of 75% in MASH and obesity. We also include gross capital raises of $50M-$100M annually from 2025E to 2027E to fund ongoing clinical development, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $1.0B and a price target of $12.
Evercore ISI
$25
Buy
344.84%
Upside
Reiterated
05/14/25
Piper Sandler
$25
Buy
344.84%
Upside
Reiterated
05/14/25
B.Riley Financial
$20
Buy
255.87%
Upside
Reiterated
05/14/25
William Blair
―
Hold
―
Reiterated
05/13/25
Jefferies
$28
Buy
398.22%
Upside
Reiterated
03/14/25
UBS
$26
Buy
362.63%
Upside
Initiated
11/11/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$5.5
Hold
-2.14%
Downside
Reiterated
05/29/25
Citizens JMP
$25
Buy
344.84%
Upside
Reiterated
06/05/25
Stifel Nicolaus
$18
Buy
220.28%
Upside
Initiated
06/01/25
H.C. Wainwright
$12
Buy
113.52%
Upside
Reiterated
05/22/25
Analysts Offer Insights on Healthcare Companies: Altimmune (NASDAQ: ALT) and Alpha Tau Medical Ltd (NASDAQ: DRTS)We assess Altimmune using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)-based methodology. We assign probabilities of success for pemvidutide (ALT-801) of 75% in MASH and obesity. We also include gross capital raises of $50M-$100M annually from 2025E to 2027E to fund ongoing clinical development, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. Taken together, these assumptions yield a total firm value of approximately $1.0B and a price target of $12.
Evercore ISI
$25
Buy
344.84%
Upside
Reiterated
05/14/25
Piper Sandler
$25
Buy
344.84%
Upside
Reiterated
05/14/25
B.Riley Financial
$20
Buy
255.87%
Upside
Reiterated
05/14/25
William Blair
―
Hold
―
Reiterated
05/13/25
Jefferies
$28
Buy
398.22%
Upside
Reiterated
03/14/25
UBS
$26
Buy
362.63%
Upside
Initiated
11/11/24
Best Analysts Covering Altimmune
1 Month
xxx
Success Rate
15/35 ratings generated profit
Average Return
+15.55%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +15.55% per trade.
3 Months
xxx
Success Rate
14/35 ratings generated profit
Average Return
+26.62%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +26.62% per trade.
1 Year
Success Rate
16/42 ratings generated profit
Average Return
+8.22%
reiterated a buy rating 2 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of +8.22% per trade.
2 Years
xxx
Success Rate
17/42 ratings generated profit
Average Return
-5.42%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.48% of your transactions generating a profit, with an average return of -5.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ALT Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
11
18
17
18
11
Buy
0
0
0
0
0
Hold
1
3
4
4
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
21
21
22
13
Each month's total comprises the sum of three months' worth of ratings.
ALT Financial Forecast
ALT Stock Forecast FAQ
What is ALT’s average 12-month price target, according to analysts?
Based on analyst ratings, Altimmune Inc’s 12-month average price target is 21.86.
What is ALT’s upside potential, based on the analysts’ average price target?
Altimmune Inc has 288.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ALT a Buy, Sell or Hold?
Altimmune Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is Altimmune Inc’s price target?
The average price target for Altimmune Inc is 21.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $28.00 ,the lowest forecast is $12.00. The average price target represents 288.97% Increase from the current price of $5.62.
The highest analyst price target is $28.00 ,the lowest forecast is $12.00. The average price target represents 288.97% Increase from the current price of $5.62.
What do analysts say about Altimmune Inc?
Altimmune Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of ALT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.